Tagged with APAC

Asia-Pacific Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a pressing need for more patient-centric, data-driven, value-based, and precise solutions in oncology. Additionally, Asian cancer patients’ healthcare needs can differ…

APAC COVID-19 has pushed diagnostics to the forefront of healthcare conversations across the world. Here, three leading lights from the Asia-Pacific medtech industry weigh in on what the new diagnostics paradigm might look like as the pandemic recedes.   Sanjay Prabhakaran, president Asia Pacific, Hologic “One positive outcome of this pandemic…

Singapore Shiva Kannan, VP and Chief Information Officer for GE Healthcare in over 120 countries, discusses the company’s journey over the past few years and the company-wide digital transformation he has led the implementation of. Moreover, he explains why GE is looking at a subscription-based model for some of their hospital…

Singapore Regulatory harmonisation for medical devices between countries in Asia-Pacific has long been a challenging issue, predominantly due to the extreme variation in cultures, economic development, governmental models, and healthcare systems in the region.   Greater harmonisation would allow solutions introduced in APAC’s most developed markets to filter down to its…

Singapore Mervyn Lim, Vice President, ResMed Asia, shares the company’s journey through COVID-19 in the region, how the company is building on their digitalisation experience, his view on how different stakeholders have to come together to improve reimbursement, and the huge opportunity in a market where 80 percent of patients with…

Singapore Leonora Lim, DHL’s Asia-Pacific VP for Life Sciences and Healthcare, Customer Solutions & Innovation, dives into the industry’s challenges during the pandemic, the continuing importance of Singapore as a regional hub, DHL’s multi-billion-dollar investment in digitalization, and why she believes that the industry will never go back to the way…

Asia-Pacific Writing in the April edition of DIA’s Global Forum magazine, Dhiraj Behl, Janine Jamieson, and Harikesh Kalonia highlight some of the regulatory challenges for drug-device combination products in APAC, including the lack of an international body dedicated to harmonisation in this field.   In the current innovation era and in the wake…

Singapore Andrew Frye of medtech giant Baxter outlines his management strategy for the diverse APAC region, how growth was achieved in 2020 despite the drop in non-essential hospital visits and treatments that the COVID-19 pandemic brought about, and the increasing importance of homecare and telehealth post-pandemic.   Healthcare is becoming more…

Singapore Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading biopharmaceutical hubs and a magnet for top talent. Multitudes of biopharma and medtech multinationals, as well as domestic start-ups, have based regional functions in the clean, English speaking, and well-developed city-state with…

Singapore Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers in Singapore and beyond, and why Asian representation in clinical trials is of vital importance moving forward.   Technology has…

Singapore Medtech industry veteran Sanjay Prabhakaran outlines the footprint and strategy of women’s health specialist Hologic in the dynamic Asia-Pacific region, how it leveraged its molecular diagnostics expertise to pivot towards COVID-19 diagnostics tests in 2020, and the leadership lessons he has learned from a 30-year corporate career with US multinationals.…

Singapore As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other markets. This situation keeps the Health Sciences Authority (HSA) – the country’s regulatory body – extremely busy. While challenges, including…